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Antibody drug conjugates (ADCs) employ the exquisite specificity of tumour-specific monoclonal antibodies (mAb) for the
targeted delivery of highly potent cytotoxic drugs to the tumour site. The chemistry of the linker, which connects the drug to the
mAb, determines how and when the drug is released from the mAb. This, as well as the chemistry of the drug, can dictate whether
the drug can diffuse into surrounding cells, resulting in ‘bystander killing’. Initially, any bystander killing mechanism of action of an
ADC was understood to involve an essential sequence of steps beginning with surface antigen targeting, internalisation,
intracellular linker cleavage, drug release, and diffusion of drug away from the targeted cell. However, recent studies indicate that,
depending on the linker and drug combination, this mechanism may not be essential and ADCs can be cleaved extracellularly or
via other mechanisms. In this minireview, we will examine the role of bystander killing by ADCs and explore the emerging
evidence of how this can occur independently of internalisation.
Ideally, anti-cancer treatments should specifically target and kill
tumour cells while leaving normal, healthy tissues relatively
unscathed. The therapeutic ratio of the maximum tolerated to
the minimally efficacious dose of many of the drugs used in
conventional cytotoxic chemotherapy is relatively low, resulting in
unwanted side-effects. Nevertheless, these drugs are relatively
effective against cancer cells because normal cells have more
efficient mechanisms for effluxing cytotoxins, repairing DNA, and
clearing dead and damaged cells. Together, these mechanisms limit
toxicity even among the rapidly dividing cells of the bone marrow
and gastrointestinal epithelium before the next cycle of che-
motherapy is given. Immunotherapy has now joined cytotoxic
chemotherapy as an effective systemic treatment for cancer, and
antibody-based therapy has contributed most significantly to this
burgeoning area. Monoclonal antibodies (mAbs) may directly stall
or kill tumour cells by binding tumour cell-specific antigens, or
indirectly kill tumour cells by inhibiting the immune checkpoint
molecules that restrain tumouricidal lymphocytes. Building on
these advances, antibody drug conjugate (ADC) therapy has
emerged with worldwide marketing approvals for the indications
of breast cancer and lymphoma.
An ADC is divided into three distinct parts – the tumour-
targeting mAb, the linker, and the cyotoxic drug, also known as the
payload or warhead (Figure 1). Modern ADC technology is
successful because the exquisite specificity of mAbs is stably
coupled with the extreme potency of new cytotoxins. Therapeutic
mAbs are commonly directed at antigens on the surface of tumour
cells themselves or the cells or other components of the supporting
tumour stroma. Ideally, these antigens are expressed at minimal
levels on normal healthy tissues but are highly expressed by
tumour cells or within the tumour microenvironment. The payload
drugs used with ADCs are orders of magnitude more potent than
conventional cytotoxic drugs, such as chemotherapeutic drugs, and
as such are too potent to use safely as free drugs for cancer therapy.
Moreover, advances in drug/linker chemistries, which enhance
plasma stability and control cytotoxin release at the tumour site,
have critically enabled modern ADC technology. Consequently,
ADCs are expected to have a higher therapeutic ratio than
conventional systemic chemotherapy.
Two ADCs are currently FDA-approved for cancer treatment;
ado-trastuzumab emtansine (KADCYLA, Roche/Genentech, San
Francisco, CA, USA) for the treatment of patients with human
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epidermal growth receptor 2 (HER2)-expressing, metastatic breast
cancer (Verma et al, 2012) and brentuximab vedotin (ADCETRIS,
Seattle Genetics, Bothell, WA, USA) for the treatment of relapsed
or refractory CD30-expressing Hodgkin lymphoma (HL) (Younes
et al, 2012) and anaplastic large cell lymphoma (ALCL) (Fanale
et al, 2012; Pro et al, 2012). A large number of early phase clinical
trials examining the therapeutic effectiveness of a range of different
ADCs are currently underway.
Although several recent reviews on ADCs have been published
covering the evolution of ADC technology through different mAbs,
linker technologies and drug payloads (such as Diamantis and
Banerji, 2016; Polakis, 2016; Lambert and Morris, 2017; Beck et al,
2017), information is lacking about the ‘bystander killing’ that can
be mediated by ADCs with particular linker and/or payload
combinations and whether internalisation of the ADC is an
essential part of its mechanism of action. In this minireview, we
will focus primarily on bystander killing by ADCs and the
mechanism(s) involved. We will illustrate the potential of ADC-
mediated bystander killing through the two contrasting clinical
examples of ado-trastuzumab emtansine and brentuximab vedotin,
and discuss whether direct antigen-mediated internalisation of the
ADC is required for bystander killing.
BYSTANDER KILLING
Bystander killing occurs when the drug from an ADC is released
either from the target cell following internalisation and degradation
of the ADC or release of the drug within the extracellular space. In
both cases, the drug is then taken up by and kills surrounding or
bystander cells, which themselves may or may not express the
ADC target antigen. How much an ADC mediates bystander
killing depends largely on factors such as the extent of ADC
internalisation after binding to the target antigen, the presence of a
non-cleavable or cleavable linker, and the hydrophobicity of the
attached cytotoxic warhead.
To exert their cytotoxic effects, ADCs such as ado-trastuzumab
emtansine, which have a non-cleavable (commonly a thioether)
linker, must be internalised by the target cell for the antibody,
rather than the linker, to be degraded before release of the drug.
This form of ADC does not produce efficient bystander killing
because, typically, it contains the potent tubulin-binding maytan-
sine derivative, DM1, and the cleaved drug product cannot enter
surrounding cells because its positive charge prevents it from
penetrating the cell membrane (Erickson et al, 2006). Therefore,
non-cleavable ADCs are primarily effective against the target
antigen-expressing cell after internalisation and are best suited to
treat cancers that have high and homogenous expression of the
target antigen (Kovtun et al, 2006).
Alternatively, ADCs may contain a cleavable linker, which can
be cleaved at a defined pH range or by specific proteases to release
the free drug. Although the resulting free drug can directly kill the
target cell, it can diffuse out of the target cell to cause bystander
killing depending on the drug type and its physicochemical
properties (Kovtun et al, 2006; Li et al, 2016; Singh et al, 2016). In
spite of a consensus that ADCs are only effective if internalised via
a cell-surface antigen, evidence is emerging to indicate that ADCs
with particular linker/drug combinations can exert cell killing
through other mechanism(s).
Current FDA-approved ADCs and bystander killing. The FDA-
approved ADC, ado-trastuzumab emtansine, comprises the
humanised mAb trastuzumab, which targets HER2, an antigen
overexpressed in E25–30% of breast cancers, with treatment with
trastuzumab alone, resulting in partial and complete responses in
metastatic breast cancer patients (Cobleigh et al, 1999). The drug-
conjugated version of trastuzumab, ado-trastuzumab emtansine,
consists of trastuzumab bound by a non-cleavable thioether linker
to DM1. Once internalised by target cells, the ADC is transported
to the endosome where it is degraded, releasing an active but cell-
impermeant drug, which kills the targeted cell. The cleaved drug
product becomes trapped inside the target cell because it includes a
positively charged lysine moiety, which cannot effectively penetrate
the cell membrane and cannot therefore elicit bystander killing
(Kovtun et al, 2006). This ADC provided significant improvement
in progression-free survival when compared with trastuzumab in
combination with docetaxel, with fewer adverse incidents reported
(Hurvitz et al, 2013). Furthermore, patients with higher than
median tumour expression of HER2 mRNA responded better to
ado-trastuzumab emtansine than those with lower than median
HER2 mRNA expression (Perez et al, 2014), indicating a
relationship between the extent of HER2 expression and respon-
siveness to treatment.
The other FDA-approved ADC uses the chimeric mAb
brentuximab to target the CD30 antigen, which is expressed at
high density on the malignant Hodgkin and Reed-Sternberg (HRS)
cell in HL and on the non-HL cells of ALCL. In contrast, normal
tissue expression of CD30 is limited to activated B and T cells
(Senter and Sievers, 2012), thymocytes during development,
uterine cells during pregnancy, and pancreatic exocrine cells
(Ansell, 2014). The ADC, brentuximab vedotin, consists of
brentuximab conjugated to the microtubule-binding auristatin,
monomethyl auristatin E (MMAE), through a protease-labile,
dipeptide valine–citrulline (vc) linker. After binding to CD30, the
ADC is internalised and transported to lysosomes where the linker
is cleaved to release the free drug. The clinical results are high rates
of durable responses among patients with a number of CD30þ
lymphomas despite great variation in lymphoma cell expression of
CD30. Among patients with relapsed or refractory HL (Younes
et al, 2012) and ALCL (Pro et al, 2012), the CD30 target antigen is
expressed strongly and uniformly on the neoplastic cells.
Notwithstanding the strong and uniform CD30 expression on
HL and ALCL cells, it was not apparent that a minimal threshold
of CD30 was required for tumour response in the pivotal studies of
brentuximab vedotin for these lymphomas (Pro et al, 2012, 2013;
Younes et al, 2012; Jacobsen et al, 2015). Conversely, in tumours of
patients with T-cell lymphomas and diffuse large B-cell lymphoma
(DLBCL), CD30 expression is more variable (Bossard et al, 2014;
Slack et al, 2014; Jacobsen et al, 2015).
Nevertheless, the CD30þ neoplastic HRS cell of HL represents
only a small proportion (0.1–10%) of the total lymphoma cell
population, which mainly comprises such reactive cell types as T
and B lymphocytes, plasma cells, eosinophils, neutrophils, macro-
phages, and fibroblasts (Brown and Staudacher, 2014). Hence,
unlike ado-trastuzumab emtansine, correlations between tumour









Figure 1. Schematic diagram of antibody drug conjugate. An antibody
drug conjugate consists of a cancer-targeting vehicle, usually the whole
or fragment of a monoclonal antibody, connected by a cleavable or non-
cleavable linker to a potent cytotoxic warhead drug. mAb, monoclonal
antibody; Fab, fragment antigen binding; SIP, small immune protein.
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have not been found for other lymphomas with variable expression
of CD30 (Fromm et al, 2012; Bartlett et al, 2013; Horwitz et al,
2014; Duvic et al, 2015; Jacobsen et al, 2015). In a phase 2 study of
35 patients with CD30þ relapsed or refractory peripheral T-cell
lymphoma who received brentuximab vedotin, there was no
apparent correlation between response and tumour CD30 expres-
sion; 9 of 14 patients (64%) had responses with little (p15%) or no
CD30 expression by central review of immunohistochemistry
(Horwitz et al, 2014). In another example, an ALCL patient, whose
skin lesion had an estimated 3% occupancy of CD30-binding sites,
obtained a complete remission after treatment with brentuximab
vedotin (Fromm et al, 2012). Again, in a phase 2 study of 48
patients with CD30þ cutaneous T-cell lymphoma, brentuximab
vedotin produced a high overall tumour response rate of 73% but
the responses did not correlate with tumour CD30 expression; even
patients with low-level expression (o10%) achieved 50% partial
response rate (Duvic et al, 2015).
Finally, there was no statistical correlation between CD30
expression in DLBCL and tumour response to brentuximab vedotin
in a phase 2 study, which included 49 relapsed or refractory DLBCL
patients, although all the responders had quantifiable CD30
expression by computer assisted digital video analysis immuno-
histochemistry (cIHC). Remarkably, one patient with relapsed
DLBCL, who had 0% CD30 expression within the tumour biopsy
by central review of visual IHC and 1.4% via cIHC, still achieved a
complete response after two cycles of brentuximab vedotin
(Jacobsen et al, 2015). In a follow-up study of 52 DLBCL patients
with absent CD30 expression by visual IHC, 16 patients (31%) had
an objective response including six complete responses (12%).
Analysis by cIHC showed that 11 of the 16 DLBCL responders had
X1% CD30, and this was associated with significantly longer
median overall survival. These data suggest that a minimum
threshold of CD30 expression is required for anti-tumour activity
of brentuximab vedotin in DLBCL (Bartlett et al, 2017).
Together, these data suggest that factors other than direct killing
of antigen-positive cells by brentuximab vedotin must be involved
as even low CD30-expressing disease can be just as responsive to
brentuximab vedotin as high CD30-expressing disease. Bystander
killing mechanisms may help to explain these observations (Brown
and Staudacher, 2014; Masuda et al, 2015). Interestingly, new DNA
minor groove binding cytotoxic warheads of picomolar potency,
which have been incorporated in ADCs have also been recently
reported to exhibit bystander killing effects in pre-clinical models
(Flynn et al, 2016; Miller et al, 2016).
Is ADC internalisation required for bystander killing? ADCs
with non-cleavable thioether linkers have particular advantages:
high stability in serum, manifest anti-tumour activity only after
internalisation and lysosomal degradation (Erickson et al, 2006),
and greatest anti-tumour efficacy with high and homogenous
tumour expression of target antigen (Kovtun et al, 2006). However,
these ADCs do not cause bystander killing because only the
tumour cells that have internalised the ADC are killed with little or
no effect on surrounding, antigen-negative cells (Kovtun et al,
2006).
Cleavable linkers include chemically labile (disulphide and pH-
dependent) and enzyme-labile (peptide-based) linkers. It is often
presumed that these linkers are cleaved only after internalisation by
the target cell with subsequent lysosomal degradation releasing free
drug. ADCs with these linkers and appropriate drugs can kill not
only the antigen-positive target cells but also the surrounding
antigen-negative cells. Consequently, these ADCs are useful for
treating tumours with heterogeneous antigen expression (Kovtun
et al, 2006; Okeley et al, 2010; Golfier et al, 2014). However,
accumulating evidence now suggests that ADC internalisation may
not be essential to facilitate tumour cell killing by these particular
types of ADC.
pH-dependent linkers. Acid-labile or pH-dependent linkers are
designed to be stable at the relatively neutral pH of blood but are
hydrolysed when in an acidic environment (pHo5). Although
degradation of the acid-labile linker in the acidic lysosome is the
major degradation pathway for drug release, studies have shown
that this may also happen extracellularly. For example, targeting
the poorly internalising antigen CD20 with an ADC consisting of
the acid-labile 4-(4-acetylphenoxy)butanoic acid (AcBut) linker
and the DNA minor groove-binding drug calicheamicin was
effective in a preclinical lymphoma model, whereas substitution
with an acid-stable (amide) linker had no anti-tumour effect when
compared with the parental antibody alone (Dijoseph et al, 2007).
Furthermore, an antibody directed against extracellular rather than
cell-surface mucin, which was conjugated via an acid-labile linker
(CL2A) to the active metabolite of irinotecan, also showed an
effective response in a preclinical pancreatic cancer model (Sharkey
et al, 2011). These results suggest that ADCs with an acid-labile
linker may not require internalisation for therapeutic potency. The
tumour microenvironment, which is much more acidic than
normal tissues because of enhanced glycoloysis and lactate
generation, may be sufficient for extracellular cleavage of the
linker.
Disulphide linkers. Disulphide linkers use a direct covalent bond
between sulphide groups belonging to the drug and linker. Two
linkers, N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP) and
N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB), which con-
tain one or two methyl groups adjacent to the disulphide bond,
respectively, resulting in increasing steric hindrance, have been
used for ADCs. The more sterically hindered SPDB linker showed
superior activity compared with the SPP linker (Erickson et al,
2010), and in some cases these cleavable linkers result in more
potent ADCs than their counterpart non-cleavable linkers (Polson
et al, 2009; Erickson et al, 2010). Although ADCs using these
linkers can cause bystander killing, it is believed that internalisa-
tion, reduction of the disulphide bond, and further modification to
the drug within the target cell are required for modifying the
potency of the drug once released from the cell to cause bystander
killing (Erickson et al, 2006, 2010; Kovtun et al, 2006; Golfier et al,
2014).
However, there are studies that indicate that internalisation of
these cleavable linker-based ADCs may not be essential for their
anti-tumour activity. For example, conjugation of the tubulin-
binding maytansine (DM1) to antibodies targeting poorly inter-
nalising antigens (CD20, CD21, CD72) via the cleavable SPP linker
were effective in xenograft models and were more effective than
ADCs with the same antibody/drug using the non-cleavable
thioether linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC) (Polson et al, 2009). In another example,
the ADC targeting the carcinoembryonic antigen cell adhesion
molecule 5 (CEACAM5) used a cleavable disulphide linker, which
is not internalised or slowly internalising, and was effective in the
treatment of colon and pancreatic xenografts (Govindan et al,
2009).
The recent ‘traceless’ technology uses a direct, unhindered
disulphide bond between a drug and an antibody or a small
immune protein (SIP). The resulting drug conjugates do not
require internalisation by the target cell because the drug is
released upon reduction or hydrolysis of the disulphide bond
within the tumour microenvironment. This technology has used a
SIP format of the F8 antibody, which binds the alternatively spliced
extracellular domain A of fibronectin, an extracellular tumour
angiogenesis marker. In preclinical studies using (SIP)F8 con-
jugated to the tubulin-binding drug, cemadotin, which is an
analogue of dolastatin and chemically related to the aurostatins,
some complete tumour regressions were observed at relatively high
daily doses of 43mg kg 1 given for 5–7 days (Bernardes et al,
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2012; Steiner et al, 2013). Conversely, substitution with a more
potent maytansanoid (DM1) resulted in much more durable
responses at lower administered doses (Perrino et al, 2014). The
mechanism of action of these ADCs depends on a reducing tumour
microenvironment to enable cleavage of the disulphide bonds
independently of ADC internalisation because the ADC does not
become internalised. It is believed that the release of thiols by dead
tumour cells may produce a self-amplifying effect, which further
increases the degradation of disulphide bonds of the drug
conjugate (Bernardes et al, 2012).
More recently, anti-tumour activity of a full-length F8 mAb
ADC, which was also conjugated via a direct disulphide bond to
the maytansinoid DM1, was observed in a teratocarcinoma
xenograft model (Gebleux et al, 2015). Strikingly, although the
F8 mAb ADC showed superior tumour uptake compared to the F8
SIP ADC (up to fourfold higher) and much greater stability in
plasma, it was less effective in controlling tumour growth
compared with F8 SIP ADC (one out of five vs three out of five
complete responders) when given at equivalent molar concentra-
tions (Gebleux et al, 2015). In this case, the ‘instability’ of the SIP-
drug interaction may actually result in quicker drug release in the
tumour resulting in higher drug accumulation.
Enzyme-labile (peptide-based) linkers. The vc dipeptide linker,
which is cleaved preferentially by the lysosomal protease, cathepsin
B, is more stable in both human and mouse plasma than the pH-
dependent hydrazone linker, resulting in lower toxicity in mice
(Doronina et al, 2003). The vc linker has been commonly used to
conjugate the tubulin-binding drugs MMAE and monomethyl
auristatin F (MMAF) to mAbs. Although structurally similar,
MMAE can readily enter cells via passive diffusion whereas MMAF
contains a charged carboxylic acid terminus, which limits its
passive diffusion into surrounding cells (Doronina et al, 2006). The
canonical pathway involved in the intracellular processing of these
particular linker/drug combinations first involves internalisation of
the ADC, transportation to the lysosome where the linker is
degraded by proteases including cathepsin B, resulting in the
release of the highly potent, free drug. Then the drug binds to
tubulins, and disrupts microtubule assembly to induce cell cycle
arrest and ultimately cell death (Figure 2). Although the low cell
permeability of MMAF limits its toxicity if the free drug is released
from the ADC before the ADC reaches the target cell, MMAF-
mediated killing is restricted to the target cell because MMAF
cannot diffuse out of the cell, and thus cannot cause bystander
killing. Consequently, MMAF ADCs require high tumour expres-
sion of target antigen to be effective (Smith et al, 2006), but are
more potent than vc-MMAE ADCs when targeting internalising
antigens in vitro (Sutherland et al, 2006). Conversely, as a free
drug, MMAE is much more potent than MMAF (50–200-fold
lower IC50) because of its increased cell permeability. Conse-
quently, MMAE has the advantage of being able to diffuse out of
the target cell and enter surrounding cells to cause bystander
killing, something that MMAF cannot do.
These findings were reinforced by a detailed study of MMAE-
containing ADCs, which showed that irrespective of the target
antigen and its expression level, the loading ratio of drug on the
antibody or the IC50 of the ADC, the concentration of MMAE
released from the targeted cell best determined the extent of
in vitro tumour cell killing (Li et al, 2016). Similarly, the
intratumoural concentration of MMAE correlated with in vivo
anti-tumour activity of the ADC. Given that these results were not
reproduced with a MMAF-containing ADC, the membrane
permeability of the released warhead and its ability to diffuse
through the tumour seemed to be required for bystander killing.
Although internalisation of vc-MMAE-based ADCs provides
one way in which they exert anti-tumour activity, studies indicate
that ADC internalisation may not be required for anti-tumour
action of these ADCs. For example, targeting the poorly
internalised antigen CD21 with an ADC containing vc-MMAF
was not effective, whereas conjugation of the same antibody with
vc-MMAE showed potent anti-tumour activity in a preclinical
lymphoma model (Polson et al, 2009), indicating that mechanisms
independent of direct internalisation by antigen binding are at
play. Furthermore, targeting of the non-internalising A1 domain of
the glycoprotein Tenascin C with an intact antibody (or a SIP)
using the vc linker and MMAE drug combination was effective,
with the ADC format capable of producing cures in mice bearing
human epidermal carcinoma and glioblastoma tumours (Gebleux
et al, 2016). Substitution of a single amino acid of the dipetide
linker of this ADC significantly altered the in vivo stability
resulting in differences in activity of the ADC, and in some cases
different cleaved drug products, whereas substitution with a non-
cleavable linker abrogated any in vivo anti-cancer activity,
confirming that a cleavable linker was essential for any anti-cancer
activity of this non-internalising ADC (Dal Corso et al, 2017).
Although not antibody-based, small molecule drug conjugates
that use an acetazolamide derivative to bind carbonic anhydrase at
the tumour cell surface do not become internalised and are
effective in treating renal carcinoma-bearing mice when linked via
cathepsin-B cleavable dipeptide linkers to MMAE or the
anthracycline analogue, PNU-159682 (Cazzamalli et al, 2016). In
this case, the more serum-stable dipeptide linkers (valine–alanine
and vc) were more active in reducing tumour growth compared
with the less-stable valine–lysine or valine–arginine linkers when
using the MMAE payload (Cazzamalli et al, 2017).
Factors contributing to ADC-mediated bystander killing of non-
internalising ADCs. As discussed above, ADCs employing a
cathepsin B cleavable linker can be cleaved independently of direct
antigen-internalisation or at least through alternative mechanisms.
Cathepsin B expression is not limited to the lysosome, particularly
in tumour cells. Tumour cells have increased membrane and
secreted levels of cathepsin B, which is an attribute of their invasive
phenotype (Poole et al, 1978; Buck et al, 1992; Sloane et al, 2005).
Furthermore, tumour associated macrophages and stromal fibro-
blasts highly express cathepsin B (Campo et al, 1994; Reddy et al,
1995). The overproduction of cathepsin B by tumour cells and
tumour-associated cells may at least be partly involved in cleavage
of ADCs present in a tumour mass either in extracellular spaces or
after target antigen binding (Figure 2). In support of this,
conditioned media from tumour cell cultures contain cathepsins,
which can cleave an ADC containing a dipeptide linker to release
free drug and cause bystander killing (Lam et al, 2014).
Furthermore, the cleavage of dipeptide linkers may not be
exclusively performed by cathepsin B, as serine hydrolase
carboxylesterase 1C can cleave the linker in rodent serum,
resulting in ADC instability (Dokter et al, 2014; Dorywalska
et al, 2016). Whether other enzymes common to the tumour
microenvironment can also cleave dipeptide linkers extracellularly
is not known.
The internalisation of ADCs after target antigen binding by
tumour-associated myeloid or immune cells may also play a role in
ADC catabolism. For example, a specific antibody bound to
CD30þ tumour cells was internalised by macrophages, and
macrophage-depletion reduced the anti-tumour efficacy of
CD30-directed immunotherapy in vivo (Oflazoglu et al, 2007).
Similar results have been seen with CD40-directed immunother-
apy, with a combined depletion of NK, neutrophil and macro-
phages completely abolishing its anti-tumour activity (Oflazoglu
et al, 2009). Furthermore, Li et al, 2017 have demonstrated that a
non-binding, cleavable ADC was effective as in vivo treatment for
human tumour xenografts, which had a significant content of
tumour associated macrophages (TAMs). This anti-tumour effect
was mediated by the Fc-mediated uptake and processing of the
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ADC by the TAMs, which then resulted in extracellular release of
MMAE and bystander tumour cell killing. It is therefore clear that
immune cells, in particular macrophages, are required for
immunotherapeutic efficacy, and these effects may be dependent
on Fc-mediated phagocytosis. However, ADCs with site-directed
mutation to reduce Fc-binding still show efficacy, meaning that in
some cases Fc-dependent effector functions are not solely required
for tumour responses to ADCs (McDonagh et al, 2008).
CONCLUSION
ADCs are revolutionising the field of cancer treatment by
harnessing the specificity of tumour-targeting mAbs with the
stability and high potency of advanced linker/drug combinations.
Although it has been established that internalisation and
intracellular processing of ADCs provide one mechanism of
action, it is becoming clear that this is not the only mechanism of
ADC action and other processing mechanisms independent of
direct cell-surface antigen internalisation can produce effective
ADCs.
Depending on the linker type and drug combination, non-
internalising ADCs may have additional advantages by exploiting
pathological features inherent to the microenvironment of many
tumours such as hypoxia, necrosis, excess reducing equivalents,
acidity, an abundance of both active extracellular proteases and
protease-rich tumour-infiltrating myeloid cells. By providing the
setting for conditional activation of ADCs, tumour properties other
than antigen specificity can enhance the tumour selectivity of
ADCs. Finally, a strong rationale exists for combining ADCs with
other cancer therapies that either act upon or react to elements of
the tumour microenvironment. For example, cytotoxic chemother-
apy drugs can increase tumour expression of ADC-catabolising
cathepsin B (Shree et al, 2011). In addition, tubulin-targeting or
DNA-binding warhead drugs consequently released in the tumour
microenvironment can be immunostimulatory and thus used to
engage the therapeutically beneficial effects of immune checkpoint
inhibitors (Muller et al, 2014; Gerber et al, 2016; Rios-Doria et al,
2017).
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